Payment overview · 2025
General Payments
$209.82
12 reported records · 8 companies
Healthcare provider profile · identity verified
Jeffrey Michael Brock, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · CHERAW, SC · NPI 1992966352
Verified facts
What the public records show
CMS Open Payments records show Jeffrey Michael Brock, M.D. received $209.82 in general payments during 2025 across 12 reported records.
Novo Nordisk Inc accounted for 20.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 116 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 146 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 238 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $43.94 | 20.9% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $37.02 | 17.6% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $33.75 | 16.1% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $33.54 | 16.0% | 2 | 2025 |
| Genmab U.S., Inc. | Unresolved — no canonical attribution shown | $18.71 | 8.9% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.73 | 7.0% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $14.30 | 6.8% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $13.83 | 6.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $209.82 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $43.94 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $43.94 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $37.02 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $33.75 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $33.75 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $33.54 | 2 | 2025 |
Source payment records
|
|||||
| Tivdak Normalized: tivdak |
Drug | Genmab U.S., Inc. | $18.71 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $14.73 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $14.30 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $14.30 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $13.83 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 116 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 70 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 238 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
116 | 43 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
31 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
146 | 46 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
70 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
85 | 18 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
238 | 45 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 361 | 109 |
| Amlodipine Besylate | Amlodipine Besylate | 343 | 96 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 259 | 42 |
| Pravastatin Sodium | Pravastatin Sodium | 256 | 82 |
| Gabapentin | Gabapentin | 245 | 68 |
| Ozempic | Semaglutide | 238 | 45 |
| Metoprolol Succinate | Metoprolol Succinate | 211 | 59 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 201 | 57 |
| Levothyroxine Sodium | Levothyroxine Sodium | 198 | 42 |
| Oxycodone Hcl | Oxycodone Hcl | 171 | 22 |
| Quetiapine Fumarate | Quetiapine Fumarate | 160 | 44 |
| Jardiance | Empagliflozin | 146 | 46 |
| Omeprazole | Omeprazole | 144 | 50 |
| Lisinopril | Lisinopril | 137 | 49 |
| Tramadol Hcl | Tramadol Hcl | 130 | 31 |
| Meloxicam | Meloxicam | 125 | 40 |
| Farxiga | Dapagliflozin Propanediol | 116 | 43 |
| Furosemide | Furosemide | 116 | 36 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 113 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 111 | 37 |
| Tamsulosin Hcl | Tamsulosin Hcl | 97 | 29 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 94 | 27 |
| Sertraline Hcl | Sertraline Hcl | 94 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 88 | 36 |
| Trulicity | Dulaglutide | 85 | 18 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 84 | 21 |
| Allopurinol | Allopurinol | 81 | 22 |
| Metformin Hcl | Metformin Hcl | 81 | 31 |
| Carvedilol | Carvedilol | 79 | 24 |
| Hydrochlorothiazide | Hydrochlorothiazide | 79 | 29 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 77 | 24 |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 76 | 20 |
| Mirtazapine | Mirtazapine | 73 | 24 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 72 | 16 |
| Losartan Potassium | Losartan Potassium | 71 | 25 |
| Mounjaro | Tirzepatide | 70 | 14 |
| Tresiba Flextouch U-200 | Insulin Degludec | 70 | 26 |
| Pantoprazole Sodium | Pantoprazole Sodium | 68 | 27 |
| Famotidine | Famotidine | 66 | 21 |
| Tresiba Flextouch U-100 | Insulin Degludec | 65 | 19 |
| Chlorthalidone | Chlorthalidone | 63 | 21 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 63 | 18 |
| Potassium Chloride | Potassium Chloride | 61 | 25 |
| Spironolactone | Spironolactone | 59 | 19 |
| Nifedipine Er | Nifedipine | 53 | 17 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 49 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 49 | 14 |
| Valsartan | Valsartan | 49 | 14 |
| Prednisone | Prednisone | 48 | 28 |
| Aripiprazole | Aripiprazole | 47 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 47 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 45 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 45 | 21 |
| Alendronate Sodium | Alendronate Sodium | 44 | 14 |
| Celecoxib | Celecoxib | 43 | 18 |
| Pregabalin | Pregabalin | 42 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 41 | 13 |
| Topiramate | Topiramate | 41 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 41 | 11 |
| Doxazosin Mesylate | Doxazosin Mesylate | 38 | 14 |
| Colchicine | Colchicine | 35 | suppressed |
| Eliquis | Apixaban | 35 | 11 |
| Xarelto | Rivaroxaban | 35 | 11 |
| Entresto | Sacubitril/Valsartan | 34 | suppressed |
| Ezetimibe | Ezetimibe | 33 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 32 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 31 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 31 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 31 | 15 |
| Donepezil Hcl | Donepezil Hcl | 30 | suppressed |
| Baclofen | Baclofen | 26 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 25 | 14 |
| Novolog Flexpen | Insulin Aspart | 25 | 11 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 25 | 11 |
| Levemir Flexpen | Insulin Detemir | 24 | 13 |
| Vraylar | Cariprazine Hcl | 24 | suppressed |
| Alprazolam | Alprazolam | 23 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 23 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 23 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 23 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | 16 |
| Finasteride | Finasteride | 22 | suppressed |
| Ibuprofen | Ibuprofen | 22 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Levetiracetam | Levetiracetam | 22 | suppressed |
| Simvastatin | Simvastatin | 22 | suppressed |
| Methadone Hcl | Methadone Hcl | 21 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 21 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 21 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 21 | suppressed |
| Fluconazole | Fluconazole | 20 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Humira Pen | Adalimumab | 19 | suppressed |
| Clonazepam | Clonazepam | 18 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Metolazone | Metolazone | 18 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 18 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 17 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | 16 |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Risperidone | Risperidone | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | 11 |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Sotalol | Sotalol Hcl | 16 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | 13 |
| Methotrexate | Methotrexate Sodium | 15 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 15 | suppressed |
| Travoprost | Travoprost | 15 | suppressed |
| Anastrozole | Anastrozole | 14 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 14 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 14 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 11 | suppressed |
| Lorazepam | Lorazepam | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Nystop | Nystatin | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | 11 |
| Terbinafine Hcl | Terbinafine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $209.82 · 12 records | Novo Nordisk Inc | Cologuard Collection Kit, Dexcom G6 Transmitter, FARXIGA, Kerendia, MOUNJARO, Ozempic, QULIPTA, Rybelsus, Tivdak, UBRELVY, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error